ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma.
Summary
This study identifies ERO1A as a novel and promising biomarker for early-stage lung adenocarcinoma (esLUAD). High ERO1A expression is associated with poor prognosis, yet paradoxically, it correlates with an immune-activated tumor microenvironment. Tumors with elevated ERO1A levels demonstrate a superior response to immune checkpoint inhibitors. This biomarker could therefore aid in patient stratification and guide peri-operative therapeutic decisions.
Analysis
🔴 CLINIQUE: ERO1A serves as an independent prognostic biomarker for overall and recurrence-free survival in early-stage lung adenocarcinoma. It also acts as a potential predictive biomarker for response to immune checkpoint inhibitors, with high ERO1A levels correlating with superior response. This could justify phase II/III clinical trials to guide peri-operative therapeutic decisions, particularly the integration of immunotherapy, potentially altering clinical practice within 3-5 years. The study relies on retrospective cohorts and IHC validations. 🟢 BIOMOL: The discovery of ERO1A as a biomarker emerged from an unbiased screening approach. High ERO1A expression is linked to enhanced proliferative pathways and, paradoxically, an immune-activated tumor microenvironment, characterized by enriched CD8+ T cell infiltration, reduced M2 macrophages, and increased mature tertiary lymphoid structures. ERO1A-high tumors also exhibit elevated TMB and PD-L1 levels. Validation was performed using immunohistochemistry (IHC) in an independent institutional cohort, demonstrating the analytical validity of protein detection. 🔵 BIOINFO: The study integrated multi-omics data from public databases (TCGA, GEO). Machine learning algorithms (LASSO, Random Forest, SVM) were employed to identify core prognostic genes, including ERO1A. Bioinformatic analyses were also used for functional enrichment, immune microenvironment analysis, and drug sensitivity prediction. Although the study did not deploy a clinical model, it utilized robust methods for biomarker identification and characterization.